INTRODUCTION: IgA nephropathy is a chronic renal disease characterized by mesangial immunodeposits that contain autoantigen, which is aberrantly glycosylated IgA1 with some hinge-region O-glycans deficient in galactose. Macroscopic hematuria during an upper respiratory tract infection is common among patients with IgA nephropathy, which suggests a connection between inflammation and disease activity. Interleukin-6 (IL-6) is an inflammatory cytokine involved in IgA immune response. We previously showed that IL-6 selectively increases production of galactose-deficient IgA1 in IgA1-secreting cells from patients with IgA nephropathy. METHODS: We characterized IL-6 signaling pathways involved in the overproduction of galactose-deficient IgA1. To understand molecular mechanisms, IL-6 signaling was analyzed by kinomic activity profiling and Western blotting, followed by confirmation assays using siRNA knock-down and small-molecule inhibitors. RESULTS: STAT3 was differentially activated by IL-6 in IgA1-secreting cells from patients with IgA nephropathy compared with those from healthy control subjects. Specifically, IL-6 induced enhanced and prolonged phosphorylation of STAT3 in the cells from patients with IgA nephropathy, which resulted in overproduction of galactose-deficient IgA1. This IL-6-mediated overproduction of galactose-deficient IgA1 could be blocked by small molecule inhibitors of JAK/STAT signaling. DISCUSSION: Our results revealed that IL-6-induced aberrant activation of STAT3-mediated overproduction of galactose-deficient IgA1. STAT3 signaling pathway may thus represent a new target for disease-specific therapy of IgA nephropathy.

Department of Immunology Faculty of Medicine and Dentistry Palacky University and University Hospital Olomouc Olomouc Czech Republic

Department of Medicine College of Physicians and Surgeons Columbia University New York USA

Department of Medicine University of Alabama at Birmingham Birmingham Alabama USA

Department of Microbiology University of Alabama at Birmingham Birmingham Alabama USA

Department of Pediatrics University of Tennessee Health Center Memphis Tennessee USA

Department of Radiation Oncology University of Alabama at Birmingham Birmingham Alabama USA

Division of Nephrology Department of Internal Medicine Juntendo University Faculty of Medicine Tokyo Japan

Medical Corporation Showakai Tokyo Japan

Zobrazit více v PubMed

Berger J., Hinglais N. [Intercapillary deposits of IgA-IgG] J Urol Nephrol. (Paris) 1968;74:694–695. PubMed

Julian B.A., Waldo F.B., Rifai A. IgA nephropathy, the most common glomerulonephritis worldwide. A neglected disease in the United States? Am J Med. 1988;84:129–132. PubMed

D'Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. 2000;36:227–237. PubMed

Conley M.E., Cooper M.D., Michael A.F. Selective deposition of immunoglobulin A1 in immunoglobulin A nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus. J Clin Invest. 1980;66:1432–1436. PubMed PMC

Hiki Y., Kokubo T., Iwase H. Underglycosylation of IgA1 hinge plays a certain role for its glomerular deposition in IgA nephropathy. J Am Soc Nephrol. 1999;10:760–769. PubMed

Allen A.C., Bailey E.M., Brenchley P.E. Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. Kidney Int. 2001;60:969–973. PubMed

Suzuki H., Kiryluk K., Novak J. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011;22:1795–1803. PubMed PMC

Wyatt R.J., Julian B.A. IgA nephropathy. N Engl J Med. 2013;368:2402–2414. PubMed

Suzuki H., Fan R., Zhang Z. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest. 2009;119:1668–1677. PubMed PMC

Tomana M., Matousovic K., Julian B.A. Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int. 1997;52:509–516. PubMed

Tomana M., Novak J., Julian B.A. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest. 1999;104:73–81. PubMed PMC

Allen A.C., Harper S.J., Feehally J. Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy. Clin Exp Immunol. 1995;100:470–474. PubMed PMC

Mestecky J., Tomana M., Crowley-Nowick P.A. Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy. Contrib Nephrol. 1993;104:172–182. PubMed

Moldoveanu Z., Wyatt R.J., Lee J.Y. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int. 2007;71:1148–1154. PubMed

Gharavi A.G., Moldoveanu Z., Wyatt R.J. Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol. 2008;19:1008–1014. PubMed PMC

Zhao N., Hou P., Lv J. The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int. 2012;82:790–796. PubMed PMC

Coppo R., Basolo B., Martina G. Circulating immune complexes containing IgA, IgG and IgM in patients with primary IgA nephropathy and with Henoch-Schoenlein nephritis. Correlation with clinical and histologic signs of activity. Clin Nephrol. 1982;18:230–239. PubMed

Novak J., Tomana M., Matousovic K. IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int. 2005;67:504–513. PubMed

Mestecky J., Raska M., Julian B.A. IgA nephropathy: molecular mechanisms of the disease. Annu Rev Pathol. 2013;8:217–240. PubMed

Levy M., Gonzalez-Burchard G., Broyer M. Berger's disease in children. Natural history and outcome. Medicine. 1985;64:157–180. PubMed

Floege J., Feehally J. The mucosa-kidney axis in IgA nephropathy. Nat Rev Nephrol. 2016;12:147–156. PubMed

Bene M.C., Faure G.C. Mesangial IgA in IgA nephropathy arises from the mucosa. Am J Kidney Dis. 1988;12:406–409. PubMed

Xie Y., Chen X., Nishi S. Relationship between tonsils and IgA nephropathy as well as indications of tonsillectomy. Kidney Int. 2004;65:1135–1144. PubMed

Kiryluk K., Novak J., Gharavi A.G. Pathogenesis of immunoglobulin A nephropathy: recent insight from genetic studies. Annu Rev Med. 2013;64:339–356. PubMed PMC

Kiryluk K., Li Y., Scolari F. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet. 2014;46:1187–1196. PubMed PMC

Suzuki H., Raska M., Yamada K. Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes. J Biol Chem. 2014;289:5330–5339. PubMed PMC

Smith A.C., Molyneux K., Feehally J. O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy. J Am Soc Nephrol. 2006;17:3520–3528. PubMed

Suzuki H., Moldoveanu Z., Hall S. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest. 2008;118:629–639. PubMed PMC

Inoue T., Sugiyama H., Hiki Y. Differential expression of glycogenes in tonsillar B lymphocytes in association with proteinuria and renal dysfunction in IgA nephropathy. Clin Immunol. 2010;136:447–455. PubMed

Sato D., Suzuki Y., Kano T. Tonsillar TLR9 expression and efficacy of tonsillectomy with steroid pulse therapy in IgA nephropathy patients. Nephrol Dial Transplant. 2012;27:1090–1097. PubMed

Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 2001;25:402–408. PubMed

Gilbert A.N., Shevin R.S., Anderson J.C. Generation of microtumors using 3D human biogel culture system and patient-derived glioblastoma cells for kinomic profiling and drug response testing. J Vis Exp. 2016:e54026. PubMed PMC

Anderson J.C., Willey C.D., Mehta A. High throughput kinomic profiling of human clear cell renal cell carcinoma identifies kinase activity dependent molecular subtypes. PLoS One. 2015;10:e0139267. PubMed PMC

Anderson J.C., Taylor R.B., Fiveash J.B. Kinomic alterations in atypical meningioma. Med Res Arch. 2015;3 10.18103/mra.v0i3.104. PubMed PMC

Le W., Liang S., Chen H. Long-term outcome of IgA nephropathy patients with recurrent macroscopic hematuria. Am J Nephrol. 2014;40:43–50. PubMed

Boyd J.K., Cheung C.K., Molyneux K. An update on the pathogenesis and treatment of IgA nephropathy. Kidney Int. 2012;81:833–843. PubMed

Mattu T.S., Pleass R.J., Willis A.C. The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fcα receptor interactions. J Biol Chem. 1998;273:2260–2272. PubMed

Diehl S., Rincon M. The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol. 2002;39:531–536. PubMed

Hurtado A., Johnson R.J. Hygiene hypothesis and prevalence of glomerulonephritis. Kidney Int. 2005;68(suppl 97):S62–S67. PubMed

Chintalacharuvu S.R., Emancipator S.N. The glycosylation of IgA produced by murine B cells is altered by Th2 cytokines. J Immunol. 1997;159:2327–2333. PubMed

Chintalacharuvu S.R., Emancipator S.N. Differential glycosylation of two glycoproteins synthesized by murine B cells in response to IL-4 plus IL-5. Cytokine. 2000;12:1182–1188. PubMed

Inoshita H., Kim B.G., Yamashita M. Disruption of Smad4 expression in T cells leads to IgA nephropathy-like manifestations. PLoS One. 2013;8:e78736. PubMed PMC

Yamada K., Kobayashi N., Ikeda T. Down-regulation of core 1 β1,3-galactosyltransferase and Cosmc by Th2 cytokine alters O-glycosylation of IgA1. Nephrol Dial Transplant. 2010;25:3890–3897. PubMed PMC

Royle L., Roos A., Harvey D.J. Secretory IgA N- and O-glycans provide a link between the innate and adaptive immune systems. J Biol Chem. 2003;278:20140–20153. PubMed

Hastings M.C., Moldoveanu Z., Julian B.A. Galactose-deficient IgA1 in African Americans with IgA nephropathy: serum levels and heritability. Clin J Am Soc Nephrol. 2010;5:2069–2074. PubMed PMC

Lin X., Ding J., Zhu L. Aberrant galactosylation of IgA1 is involved in the genetic susceptibility of Chinese patients with IgA nephropathy. Nephrol Dial Transplant. 2009;24:3372–3375. PubMed

Qin W., Zhou Q., Yang L.C. Peripheral B lymphocyte β1,3-galactosyltransferase and chaperone expression in immunoglobulin A nephropathy. J Intern Med. 2005;258:467–477. PubMed

Malycha F., Eggermann T., Hristov M. No evidence for a role of cosmc-chaperone mutations in European IgA nephropathy patients. Nephrol Dial Transplant. 2009;24:321–324. PubMed

Kiryluk K., Li Y., Moldoveanu Z. GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway. PLoS Genet. 2017;13:e1006609. PubMed PMC

Rostoker G., Rymer J.C., Bagnard G. Imbalances in serum proinflammatory cytokines and their soluble receptors: a putative role in the progression of idiopathic IgA nephropathy (IgAN) and Henoch-Schönlein purpura nephritis, and a potential target of immunoglobulin therapy? Clin Exp Immunol. 1998;114:468–476. PubMed PMC

Panichi V., Migliori M., De Pietro S. C-reactive protein and interleukin-6 levels are related to renal function in predialytic chronic renal failure. Nephron. 2002;91:594–600. PubMed

Ranieri E., Gesualdo L., Petrarulo F. Urinary IL-6/EGF ratio: a useful prognostic marker for the progression of renal damage in IgA nephropathy. Kidney Int. 1996;50:1990–2001. PubMed

Papanicolaou D.A., Wilder R.L., Manolagas S.C. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 1998;128:127–137. PubMed

Gharavi A.G., Kiryluk K., Choi M. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet. 2011;43:321–327. PubMed PMC

Imielinski M., Baldassano R.N., Griffiths A. Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet. 2009;41:1335–1340. PubMed PMC

Liu J.Z., van Sommeren S., Huang H. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015;47:979–986. PubMed PMC

Anglesio M.S., George J., Kulbe H. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res. 2011;17:2538–2548. PubMed

Jones S.A., Scheller J., Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest. 2011;121:3375–3383. PubMed PMC

Bende R.J., Jochems G.J., Frame T.H. Effects of IL-4, IL-5, and IL-6 on growth and immunoglobulin production of Epstein-Barr virus-infected human B cells. Cell Immunol. 1992;143:310–323. PubMed

Lin L., Benson D.M., Jr., DeAngelis S. A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells. Int J Cancer. 2012;130:1459–1469. PubMed PMC

Lue C., Kiyono H., McGhee J.R. Recombinant human interleukin 6 (rhIL-6) promotes the terminal differentiation of in vivo-activated human B cells into antibody-secreting cells. Cell Immunol. 1991;132:423–432. PubMed

Heinrich P.C., Behrmann I., Haan S. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374:1–20. PubMed PMC

Zeng J., Mi R., Wang Y. Promoters of human Cosmc and T-synthase genes are similar in structure, yet different in epigenetic regulation. J Biol Chem. 2015;290:19018–19033. PubMed PMC

Al Khatib S., Keles S., Garcia-Lloret M. Defects along the Th17 differentiation pathway underlie genetically distinct forms of the hyper IgE syndrome. J Allergy Clin Immunol. 2009;124:342–348. 348.e1–5. PubMed PMC

Milner J.D., Brenchley J.M., Laurence A. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature. 2008;452:773–776. PubMed PMC

Baran-Marszak F., Boukhiar M., Harel S. Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma. Haematologica. 2010;95:1865–1872. PubMed PMC

Cheng F., Wang H., Horna P. Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells, leading to effective antitumor immunity. Cancer Res. 2012;72:4440–4448. PubMed PMC

Koskela H.L., Eldfors S., Ellonen P. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012;366:1905–1913. PubMed PMC

Vogel T.P., Milner J.D., Cooper M.A. The ying and yang of STAT3 in human disease. J Clin Immunol. 2015;35:615–623. PubMed PMC

Munoz J., Dhillon N., Janku F. STAT3 inhibitors: finding a home in lymphoma and leukemia. Oncologist. 2014;19:536–544. PubMed PMC

Forbes L.R., Milner J., Haddad E. Signal transducer and activator of transcription 3: a year in review. Curr Opin Hematol. 2016;23:23–27. PubMed PMC

Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy

GalNAc-T14 may Contribute to Production of Galactose-Deficient Immunoglobulin A1, the Main Autoantigen in IgA Nephropathy

Galactose-Deficient IgA1 B cells in the Circulation of IgA Nephropathy Patients Carry Preferentially Lambda Light Chains and Mucosal Homing Receptors

Leukemia Inhibitory Factor Signaling Enhances Production of Galactose-Deficient IgA1 in IgA Nephropathy